Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 13/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 8/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.52 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.41 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.41 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18570634 | 0.83 | GRIK1 (0.52) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL10279982 | 0.83 | GRIK1 (0.52) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL13966046 | 0.82 | — | — | |
| SCHEMBL3617857 | 0.82 | — | — | |
| SCHEMBL3508713 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL7214839 | 0.80 | GRIK1 (0.58) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| Hydrochloric Acid SCHEMBL7214840 | 0.80 | GRIK1 (0.58) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL2491511 | 0.78 | GRIK1 (0.48) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| SCHEMBL10187359 | 0.77 | NOS2 (0.46) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL5050477 | 0.75 | SLC1A1 (0.53) | GRIK1GRIK2GRM1GRM2SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-9962450-B2 | Method of treating heart failure with modified relaxin polypeptides | AMBRX, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170226178-A1 | THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES | AMBRX, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9637441-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9567386-B2 | Therapeutic uses of modified relaxin polypeptides | AMBRX, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20110294161-A1 | Modified Human Growth Hormone | AMBRX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110288279-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110207914-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | AMBRX, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110178029-A1 | Modified Human Apolipoprotein A-1 and Their Uses | AMBRX, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110172401-A1 | Modified FGF-21 Polypeptides and Their Uses | AMBRX, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110124880-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110118501-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118451-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7928163-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110015345-A1 | Modified FGF-23 Polypeptides and Their Uses | AMBRX, INC. (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178029-A1 | Modified Human Apolipoprotein A-1 and Their Uses | APOB, APOL1, HDLBP | GRIK1 3781/4885GRIK2 4619/4885GRM1 2850/4885 |
| US-20110288279-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | GRIK1 4272/4885GRIK2 4142/4885GRM1 2943/4885 |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, TAP2 | GRIK1 4498/4885GRIK2 1917/4885GRM1 4637/4885 |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | GRIK1 4775/4885GRIK2 4675/4885GRM1 3607/4885 |
| US-20110118501-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | GRIK1 4272/4885GRIK2 4142/4885GRM1 2943/4885 |
| US-20110172401-A1 | Modified FGF-21 Polypeptides and Their Uses | FGF2, FGF1, FGF23 | GRIK1 2144/4885GRIK2 2161/4885GRM1 2884/4885 |
| US-20110124880-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | GRIK1 4272/4885GRIK2 4142/4885GRM1 2943/4885 |
| US-20110118451-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | GRIK1 4272/4885GRIK2 4142/4885GRM1 2943/4885 |
| US-20110015345-A1 | Modified FGF-23 Polypeptides and Their Uses | FGF23, FGF2, FGF1 | GRIK1 2042/4885GRIK2 1747/4885GRM1 2870/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | GRIK1 771/4885GRIK2 882/4885GRM1 247/4885 |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP4 | GRIK1 2141/4885GRIK2 2045/4885GRM1 2494/4885 |
| US-20110207914-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | FGB, FCGR3B, FCGR2A | GRIK1 4278/4885GRIK2 4292/4885GRM1 3976/4885 |
| US-20170226178-A1 | THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES | RXFP1, RXFP2, RXFP3 | GRIK1 1629/4885GRIK2 1645/4885GRM1 1448/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | GRIK1 4755/4885GRIK2 4620/4885GRM1 3803/4885 |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | RXFP1, RXFP2, RXFP3 | GRIK1 1657/4885GRIK2 1661/4885GRM1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.